Literature DB >> 10351669

Raising the quality of cost-utility analyses: lessons learnt and still to learn.

K Gerard1, I Smoker, J Seymour.   

Abstract

Heightened awareness by health care funders of the need to find more efficient ways of using scarce health care resources has led to greater demand for evidence of cost-effectiveness. Implicit in this demand is that evidence is generated using clear reporting and accepted methods. The research reported here updates an earlier review of published cost-utility analyses (CUAs) to address whether previously identified gaps in reporting have diminished over time. Raising CUA standards requires systematic and regular reviews of published material to allow adequate monitoring and evaluation. There is also a need to 'appraise the appraisers' in the sense of reviewing peer-review processes. This is particularly so in those journals which are growing in importance as outlets for economic evaluation information. The findings from this study indicate continuing variation in the quality of reporting. At the lower end of this spectrum improvements could be made in the reporting of comparators, in the clarity of effectiveness evidence, in the assignment of utility weights to health states and in reporting of sensitivity analysis. CUAs published in peer-reviewed specialist medical journals were more likely to be lower in quality suggesting guidance on the appraisal of economic submissions needs to be extended to the editors of these particular journals. These findings could be used to help to target attempts to raise the quality of evidence-based CUA information.

Mesh:

Year:  1999        PMID: 10351669     DOI: 10.1016/s0168-8510(98)00061-x

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  12 in total

1.  Quality of economic evaluations in health care.

Authors:  Tom Jefferson; Vittorio Demicheli
Journal:  BMJ       Date:  2002-02-09

Review 2.  Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations.

Authors:  Kun-Sei Lee; Werner B F Brouwer; Sang-Il Lee; Hye-Won Koo
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

4.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Twenty years of cost-effectiveness analysis in medical imaging: are we improving?

Authors:  Hansel J Otero; Frank J Rybicki; Dan Greenberg; Peter J Neumann
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

6.  Methodological reviews of economic evaluations in health care: what do they target?

Authors:  Maria-Florencia Hutter; Roberto Rodríguez-Ibeas; Fernando Antonanzas
Journal:  Eur J Health Econ       Date:  2013-08-24

Review 7.  Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.

Authors:  Rahul Jain; Michael Grabner; Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

8.  Improving the quality of abstract reporting for economic analyses in oncology.

Authors:  M Y Ho; K K Chan; S Peacock; W Y Cheung
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

9.  The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review.

Authors:  Paul Gavaza; Karen Rascati; Carolyn Brown; Kenneth Lawson; Teresa Mann
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

10.  Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.

Authors:  M G Franzosi; M Brunetti; R Marchioli; R M Marfisi; G Tognoni; F Valagussa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.